FilingSEC EDGAR8-K
NeOnc Technologies to Present NEO100 and NEO212 Clinical Data at SNO Annual Meeting
· SEC accepted
StageData Presentation Scheduled
Filing content
The company will present data from its intranasal NEO100 and oral NEO212 programs in two posters on November 13 at the 31st Annual Meeting of the Society for Neuro-Oncology.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…